The CleanPlex® Hypertrophic Cardiomyopathy (HCM) Panel is a pre-designed and made-to-order multiplex PCR / amplicon-based targeted sequencing assay for examining the germline variants or mutations across 72 genes associated with Hypertrophic Cardiomyopathy (HCM).
CleanPlex® Hypertrophic Cardiomyopathy (HCM) Panel
The CleanPlex® Hypertrophic Cardiomyopathy (HCM) Panel is a pre-designed and made-to-order multiplex PCR / amplicon-based targeted sequencing (NGS) assay designed to examine the germline variants or mutations across 72 genes associated with Hypertrophic Cardiomyopathy (HCM). The panel targets all the exonic regions of those genes and the flanking intronic sequences. Compatible with just 10 ng of DNA, sequencing-ready libraries can be prepared using a streamlined workflow in just 3 hours. The pre-designed panel is optimized in silico to deliver data with high on-target performance and high coverage uniformity to ensure efficient use of sequencing reads.
This product is made to order. Once we receive your order, we will synthesize the panel and the kit will contain CleanPlex Multiplex PCR Primers and CleanPlex Targeted Library Kit. CleanPlex Indexed PCR Primers and CleanMag® Magnetic Beads can be ordered separately to complete the workflow from input DNA to sequencing-ready NGS libraries.
Store at -20 °C.
For Research Use Only. Not for use in diagnostic procedures.
ACTC1, ACTN2, CAV3, CSRP3, GLA, LAMP2, MYBPC3, MYH7, MYL2, MYL3, PLN, PRKAG2, TCAP, TNNC1, TNNI3, TNNT2, TPM1, TTR, VCL, BAG3, DES, FHL1, FLNC, GAA, LDB3, ANKRD1, JPH2, MYH6, MYLK2, MYPN, NEXN, TTN, ABCC9, AGL, CACNA1C, CRYAB, KRAS, MYOZ2, PDLIM3, PTPN11, RAF1, RYR2, SOS1, BRAF, CALR3, DMD, DSC2, DSG2, DSP, DTNA, EMD, FKTN, GATA4, GATAD1, HRAS, ILK, JUP, LAMA4, LMNA, MAP2K1, MAP2K2, NEBL, NRAS, PKP2, RBM20, RIT1, SCN5A, SGCD, SHOC2, TAZ, TMEM43, TMPO
Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578-89.
Semsarian C. Update on the Diagnosis and Management of Hypertrophic Cardiomyopathy. Heart Lung Circ. 2018;27(3):276-279.
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761-96.
Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358(18):1899-908.
Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54.
Crocini C, et al. Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue. Basic Res Cardiol. 2013 May;108(3):349.
Online Mendelian Inheritance in Man: http://www.omim.org/
|Dimensions||10 x 7 x 5 cm|
|Pack Size (Reactions)|